AstraZeneca Gains EU Approval for Datroway in Metastatic TNBC with Daiichi Sankyo

The European Commission approved Datroway, developed by AZN with partner Daiichi Sankyo, on July 31, 2026 as a first-line monotherapy for adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1 or PD-L1 immunotherapy. Datroway is a TROP2-directed antibody-drug conjugate, and the approval makes it the only medicine in its class carrying this indication in the EU.

The clearance rests on the Phase 3 TROPION-Breast02 trial, which showed median overall survival of 23.7 months against 18.7 months for chemotherapy and a 43% reduction in the risk of disease progression or death. Triple-negative breast cancer is the most aggressive common breast cancer subtype, and the population that cannot receive immunotherapy has had comparatively few first-line options, which is what gives the label its commercial weight.

The approval extends AstraZeneca's oncology franchise at a point when the company is leaning on that portfolio for growth, and it deepens a Daiichi Sankyo partnership that already spans Enhertu. Revenue contribution will build over launch quarters rather than appear immediately, and will depend on national reimbursement decisions across EU member states, which typically lag central approval by several months to a year.

What to watch: pricing and reimbursement outcomes in Germany, France, and the UK, uptake against existing chemotherapy standards, and readouts from the broader TROPION program that could widen the label further.

Related Stocks

• AZN